Back to top
China
Firm | Deal | Value | Client | Lawyer(s) involved |
Kirkland & Ellis | Yonghui Superstores’ and Bain Capital’s takeover of Daymon Worldwide | $413 million | Bain Capital | Nicholas Norris, Gary Li, Amie Tang Derek Poon, Matthew O’Brien, Christopher Thomas (Partners)
|
Llinks Law Offices | Yonghui Superstores’ and Bain Capital’s takeover of Daymon Worldwide | $413 million | Yonghui Superstores |
|
Haiwen & Partners | Yonghui Superstores’ and Bain Capital’s takeover of Daymon Worldwide | $413 million | Bain Capital |
|
McDermott Will & Emery | Yonghui Superstores’ and Bain Capital’s takeover of Daymon Worldwide | $413 million | Daymon Worldwide |
|
Paul Hastings | Xuebajun’s Series C Financing | $100 million | Xuebajun | Nan Li (Partner)
Joyce Du, Eva Gao (Associates)
|
David Polk & Wardwell | Yanlord Land Group’s Regulation S offering of 5.875% senior notes due 2022 | $450 Million | Yanlord Land Group | William F. Barron (Partner)
Faisal Baloch, Alon Gurfinkel (Counsels)
Jennifer Liu and Lin Ma (Registered Foreign Lawyers)
Kelli A. Rivers (Associate) |
Back to top
Hong Kong
Firm | Deal | Value | Client | Lawyer(s) involved |
Shearman & Sterling | $830 million | Golden Meditech | Paul Strecker (Partner) | |
Zhong Lun | $830 million | China Cord Blood |
| |
Paul Hastings | Yuzhou Properties’ offering of 6.00% Senior Notes due 2023 | $250 million | Yuzhou Properties | Vivian Lam, James Ma (Partners)
Jeff Lee, May Lun, Stern Liu (Associates) |
Paul Hastings | Yuzhou Properties’ offering of 6.00% Senior Notes due 2022 | $350 million | Yuzhou Properties’ | Vivian Lam, James Ma (Partners)
Jeff Lee, May Lun, Stern Liu (Associates) |
Sullivan & Cromwell | Aviva, Hillhouse Capital and Tencent Holdings’ joint venture for a digital insurance company |
| Aviva | Chun Wei, Garth W. Bray, Kay Ian Ng (Partners)
Robert M. Fettman (Special Counsel)
Jordan H. Oreck, Alan Hongye Zhang, Vincent W. Lee (Associates) |
Back to top
Japan
Firm | Deal | Value | Client | Lawyer(s) involved |
Cleary Gottlieb Steen & Hamilton | $5.2 billion | Takeda Pharmaceutical |
| |
Paul, Weiss, Rifkind, Wharton & Garrison.
| $5.2 billion | Ariad Pharmaceuticals |
| |
Mori Hamada & Matsumoto | $1.3 billion | Hitachi Koki |
| |
Nishimura & Asahi | $1.3 billion | Kohlberg Kravis Roberts (KKR) |
| |
Simpson Thacher & Bartlett | $1.3 billion | Kohlberg Kravis Roberts (KKR) | David Sneider (Partner) |
